Case Study · Laboratory Startup

Planning an in-house molecular lab in the
Mid-South

Alliant built a startup plan for an in-house molecular lab. The plan projected about $115,000 in upfront investment, an all-in cost of about $60 per test, and cumulative breakeven in month 5 of operation.

Laboratory Startup

Projected

The plan at a glance

All figures are projections from the client's startup financial model, not achieved results.

Test menu

UTI, STI & vaginosis

PCR panels

Annual volume

9,500

samples (~790/month)

Upfront investment

$115,060

projected

All-in cost per test

$60.10

projected

Avg. reimbursement per sample

$156.32

projected

Cumulative breakeven

Month 5

of operation, projected

The challenge

Paying another lab for work it could do itself.

The client was sending its UTI, STI, and vaginosis testing to an outside reference lab, paying another lab for high-volume work it could do itself while waiting longer for results. Before committing capital, it needed four answers:

  1. 01Which tests would cover their cost, and by how much?
  2. 02What would each test cost to run, including reagents, QC, staff, and software?
  3. 03How much cash would it take to open the lab?
  4. 04How long until the lab paid back that investment?

Alliant's approach

A test-by-test financial model.

Alliant built a test-by-test financial model linking the clinical menu to the CPT codes, costs, and cash needs behind it.

  1. 01

    Test menu design

    Multiplex PCR panels for UTI (pathogens plus antibiotic-resistance genes), STI (gonorrhea, chlamydia, trichomonas, HSV-1/2, and Mycoplasma genitalium), and vaginosis, with HPV and wound panels as later options.

  2. 02

    CPT mapping

    Every target on each panel was matched to its CPT code, so reimbursement estimates rested on billable codes, not guesses.

  3. 03

    Cost per test

    Reagent, QC, collection-kit, consumable, proficiency-testing, and billing costs per panel, plus fixed costs for lab leadership, a supervisor, LIMS reporting, and instrument service.

  4. 04

    Startup budget

    Validation studies, build-out, initial supplies, and first assay purchases combined into one upfront figure, plus a cash reserve.

  5. 05

    Breakeven timeline

    A 28-month cash projection comparing cumulative spending to cumulative revenue, allowing two months for setup and validation before the first billable test.

Financial model

Projected

Where the returns come from.

$1.49M

Projected annual gross revenue

$570,925

Projected operating costs

62%

Projected margin

The STI panel carried most of the volume, while vaginosis contributed nearly as much revenue on half the samples.

What the plan gave the client

A clear go/no-go decision.

A clear go/no-go decision based on its own test menu and costs, not industry averages. The model showed which panels would drive returns, set the cash needed to open, and put a timeline on payback. It became the working plan for next steps, including validation, director and supervisor coverage, and billing setup.